Literature DB >> 20667250

Reversibility of ischemia evaluated by ischemic duration and residual cerebral blood flow.

S Nakano1, T Iseda, T Goya, S Wakisaka.   

Abstract

SUMMARY: We first investigated the time course of CBF thresholds of ischemic cortices by a retrospective review of 19 patients with MCA occlusion who had clearly defined ischemic duration from onset to angiographic complete recanalization. Secondly, CBF thresholds of ischemic cortices salvageable with intravenous low dose native t- PA infusion therapy (7.2 mg of tisokinase) were examined by a retrospective review of 20 patients with distal embolic occlusions of MCA divisions or branches. All patients underwent pretreatment CBF measurement by SPECT using 99mTc-ECD. Pretreatment SPECT and 3 months post-treatment CT images were compared using computerized coregistration. The degree of hypoperfusion was analyzed by an asymmetry index (AI), which was a count-density ratio for the ischemic lesion to the contralateral corresponding area. Ischemic cortices on SPECT were divided into reversible and irreversible lesions. Judging from the regression lines with 95% confidence interval between the ischemic duration and AI, the infarcted CBF thresholds at 3 and 6 hours after onset may be about 30 and 50% of contralateral presumed normal CBF, respectively. On the other hand, to save the ischemic tissue with our intravenous t-PA infusion therapy, residual CBF might be needed at least 45% of contralateral presumed normal CBF. It is likely that CBF threshold of ischemia surely salvageable with our intravenous t-PA infusion therapy may be approximately 50-55% of contralateral presumed normal CBF.

Entities:  

Year:  2001        PMID: 20667250      PMCID: PMC3685921          DOI: 10.1177/15910199000060S134

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  14 in total

1.  Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.

Authors:  E C Haley; D E Levy; T G Brott; G L Sheppard; M C Wong; G L Kongable; J C Torner; J R Marler
Journal:  Stroke       Date:  1992-05       Impact factor: 7.914

2.  Critical cerebral blood flow thresholds studied by SPECT using xenon-133 and iodine-123 iodoamphetamine.

Authors:  S Nakano; K Kinoshita; S Jinnouchi; H Hoshi; K Watanabe
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

3.  Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion.

Authors:  S Nakano; K Yokogami; H Ohta; T Yano; T Ohnishi
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

4.  Differential regional vulnerability in transient focal cerebral ischemia.

Authors:  F W Marcoux; R B Morawetz; R M Crowell; U DeGirolami; J H Halsey
Journal:  Stroke       Date:  1982 May-Jun       Impact factor: 7.914

5.  Intravenous low-dose native tissue plasminogen activator for distal embolism in the middle cerebral artery divisions or branches: a pilot study.

Authors:  S Nakano; T Iseda; T Yoneyama; T Ikeda; S Wakisaka
Journal:  Neurosurgery       Date:  2000-04       Impact factor: 4.654

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Thresholds of focal cerebral ischemia in awake monkeys.

Authors:  T H Jones; R B Morawetz; R M Crowell; F W Marcoux; S J FitzGibbon; U DeGirolami; R G Ojemann
Journal:  J Neurosurg       Date:  1981-06       Impact factor: 5.115

8.  Outcome in acute stroke with successful intra-arterial thrombolysis and predictive value of initial single-photon emission-computed tomography.

Authors:  T Ueda; S Sakaki; W T Yuh; I Nochide; S Ohta
Journal:  J Cereb Blood Flow Metab       Date:  1999-01       Impact factor: 6.200

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.